Research programme: antipsychotic therapeutics- Qrono

Drug Profile

Research programme: antipsychotic therapeutics- Qrono

Alternative Names: QR 110; QR 113; QR 114

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Qrono
  • Class Antipsychotics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Psychiatric disorders

Highest Development Phases

  • Research Psychiatric disorders

Most Recent Events

  • 02 Aug 2017 Research programme: antipsychotic therapeutics- Qrono is available for licensing as of 02 Aug 2017. http://qrono.com/pipeline/ (Qrono pipeline, August 2017)
  • 02 Aug 2017 Early research in Psychiatric disorders in USA (Parenteral) (Qrono pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top